{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:43:12Z","timestamp":1791996192179,"version":"4.4.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,4,14]]},"DOI":"10.1001\/jama.2020.1906","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T12:02:25Z","timestamp":1585310545000},"page":"1353","source":"Crossref","is-referenced-by-count":450,"title":["Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes"],"prefix":"10.1001","volume":"323","author":[{"given":"Mark C.","family":"Petrie","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St Michael\u2019s Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Belohl\u00e1vek","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Cardiovascular Medicine, General Teaching Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Department of Medicine, Saarland University Hospital, Homburg\/Saar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chern-En","family":"Chiang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"National Yang-Ming University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Chopra","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medanta, Gurgaon, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirta","family":"Diez","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Drozdz","sequence":"additional","affiliation":[{"name":"Department Cardiology, Medical University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Duk\u00e1t","sequence":"additional","affiliation":[{"name":"Fifth Department of Internal Medicine, Comenius University in Bratislava, Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Cardiovascular Disease, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Howlett","sequence":"additional","affiliation":[{"name":"Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzvetana","family":"Katova","sequence":"additional","affiliation":[{"name":"Clinic of Cardiology, National Cardiology Hospital, Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kitakaze","sequence":"additional","affiliation":[{"name":"Cardiovascular Division of Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotta E. A.","family":"Ljungman","sequence":"additional","affiliation":[{"name":"Institute of Medicine, Department of Molecular and Clinical Medicine\/Cardiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose C.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Instituto do Coracao (InCor), Hospital das Cl\u00ednicas Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"O'Meara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Montreal Heart Institute, Montreal, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham Nguyen","family":"Vinh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tan Tao University, Tan Duc, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Gentofte University Hospital Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Tereshchenko","sequence":"additional","affiliation":[{"name":"Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Department of Cardiology Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"St Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[{"name":"Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Universidad Nacional de C\u00f3rdoba, C\u00f3rdoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Center for Heart Diseases, University Hospital, Wroclaw Medical University, Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Sj\u00f6strand","sequence":"additional","affiliation":[{"name":"Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Johanson","sequence":"additional","affiliation":[{"name":"Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Greasley","sequence":"additional","affiliation":[{"name":"Early Discovery and Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boulton","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Bengtsson","sequence":"additional","affiliation":[{"name":"Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"joi200021r1","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.","volume":"51","author":"Meng","year":"2008","journal-title":"J Med Chem"},{"issue":"4","key":"joi200021r2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/clpt.2011.16","article-title":"Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.","volume":"89","author":"Pfister","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"joi200021r3","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"issue":"22","key":"joi200021r4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"joi200021r5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"joi200021r6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"joi200021r7","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial.","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"joi200021r8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME trial.","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"joi200021r9","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ejhf.2019.21.issue-7","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"joi200021r10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.pcad.2019.07.005","article-title":"Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes.","volume":"62","author":"Garg","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"issue":"15","key":"joi200021r11","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics.","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"joi200021r12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ejhf.2019.21.issue-5","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"joi200021r13","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"joi200021r16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jacc.2017.12.048","article-title":"2017 Cardiovascular and stroke endpoint definitions for clinical trials.","volume":"71","author":"Hicks","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"joi200021r17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure.","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"joi200021r18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/rssb.2000.62.issue-4","article-title":"Semiparametric regression for the mean and rate functions of recurrent events.","volume":"62","author":"Lin","year":"2000","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"3","key":"joi200021r19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/pst.v15.3","article-title":"A win ratio approach to comparing continuous non-normal outcomes in clinical trials.","volume":"15","author":"Wang","year":"2016","journal-title":"Pharm Stat"},{"key":"joi200021r20","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc19-S002","article-title":"2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2019.","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"joi200021r21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e4624","article-title":"Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance.","volume":"345","author":"Chatterton","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"joi200021r22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? a differential volume regulation hypothesis.","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"joi200021r23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdiacomp.2015.10.012","article-title":"EMPA-REG - the \u201cdiuretic hypothesis\u201d.","volume":"30","author":"McMurray","year":"2016","journal-title":"J Diabetes Complications"},{"issue":"5","key":"joi200021r24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.clinthera.2014.02.022","article-title":"Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.","volume":"36","author":"Devineni","year":"2014","journal-title":"Clin Ther"},{"issue":"18","key":"joi200021r25","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial.","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"joi200021r26","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.jdiacomp.2017.02.001","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.","volume":"31","author":"Kosiborod","year":"2017","journal-title":"J Diabetes Complications"},{"issue":"10","key":"joi200021r27","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications.","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"joi200021r28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging.","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"joi200021r29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.14740\/jocmr2857w","article-title":"A possible mechanism for renoprotective effect of sodium-glucose cotransporter 2 inhibitor: elevation of erythropoietin production.","volume":"9","author":"Yanai","year":"2017","journal-title":"J Clin Med Res"},{"issue":"10","key":"joi200021r30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11886-019-1219-4","article-title":"Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors.","volume":"21","author":"Wojcik","year":"2019","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"joi200021r31","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"joi200021r32","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial.","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"joi200021r14","unstructured":"US Department of Health and Human Services. Guidance for Industry: Diabetes Mellitus\u2014Evaluating Cardiovascular Risk in New Antidiabetic Therapies to treat Type 2 Diabetes. US Food and Drug Administration; 2008. Accessed December 3, 2019. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diabetes-mellitus-evaluating-cardiovascular-risk-new-antidiabetic-therapies-treat-type-2-diabetes"},{"key":"joi200021r15","unstructured":"Collection of Race and Ethnicity Data in Clinical Trials: Guidance for Industry and Food and Drug Administration Staff. US Food and Drug Administration; 2016. Accessed December 3, 2019. https:\/\/www.fda.gov\/media\/75453\/download"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2763950\/jama_petrie_2020_oi_200021_1617397932.1056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T11:46:38Z","timestamp":1617709598000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2763950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":32,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,4,14]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.1906","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,14]]}}}